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New Data on HIV Reservoirs: Implications for Therapy
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For years now, AIDS researchers have suspected that most
investigations have been focusing on the wrong site, i.e.
blood. In fact, it has been well known for over a decade
that lymphoid tissue is the key viral replication site from
the start of infection, and also a major reservoir and
source of virus at all stages of the disease. Lymphoid tissue
studies in humans have been impeded by difficulties in
obtaining material and, first and foremost, in reiterating
sampling. Recent findings in the SIV-infected macaque
model pinpoint the intestinal mucosal immune system as
a key site of viral replication/persistence and CD4 deple-
tion, even in subjects with undetectable blood virus dur-
ing therapy. These studies demonstrate that acute SIV and
HIV infections are coupled with a dramatic and selective
loss of memory CD4 T cells in lymphoid tissue, due to
direct virus-induced cytolysis or immune-mediated mech-
anisms (Mattapallil JJ et al, Nature 2005; 434: 1093-7).
Treatment strategies based primarily on blood viral load
and circulating CD4 cell counts are hence misguided.
These findings plead for HAART initiation as early as pos-
sible, and will also have implications for vaccine develop-
ment.
Data have recently been published on the potential to
decrease the latent HIV reservoir in humans by initiating
HAART at acute infection (Strain MC et al, J Infect Dis
2005; 191: 1410-8). Although failure to recover infectious
virus from these patients certainly does not reflect the
elimination of latently infected cells, these data are
encouraging in the search of new strategies combining
HAART and immune interventions.
Despite its major effect on plasma viremia, HAART initi-
ated at the chronic stage of the disease is known to have
several major drawbacks, i.e. its inability to achieve HIV
eradication due to poor targeting of the reservoir of latent
but replication-competent virus, plus the inadequate dif-
fusion of antiretroviral drugs in the various anatomic res-
ervoirs. For example, it has been clearly demonstrated that
some molecules in the combination are unable to reach
the central nervous system or genital tract well enough to
block viral replication, hence potentially creating sanctu-
aries of resistant virus. More recently, parallels have been
made between the notion of cellular resistance to antiret-
roviral drugs and the resistance of some cancer cells to
drugs. This resistance can involve efflux molecules like P-
glycoprotein (MDR-1) and Multi-drug Resistance Protein
(MRP). We investigated the expression of MDR-1, MPR-1
and MRP-4 mRNA levels in PBMC and lymph node cells
(LNMC) in 15 HIV-infected patients on long-term effec-
tive PI-based HAART regimens (plasma viremia <20 cop-
ies/ml) versus controls (HIV-uninfected, HIV-infected
HAART-naïve, HIV-infected on non-PI-based HAART).
MDR-1, MPR-1 and MRP-4 mRNA levels were measured
by PCR related to GAPDH expression and results given in
arbitrary units. We found MDR-1 mRNA expression in
PBMC to be much higher in HIV-infected but naïve
patients than HIV-negative controls (46.64 vs 0.24), and
higher in treated versus untreated patients, with no differ-
ences according to therapy type (no PI: 210.54, PI:
348.96). Surprisingly, MDR-1 expression in LNMC from
PI-treated patients was significantly lower (0.97) than in
paired PBMC. MRP-1 and MRP-4 expression showed sig-
nificantly higher expression in HIV-treated versus HIV-
negative patients, with no differences according to therapy
type, and similar expression in HIV-infected untreated
patients versus HIV-negative controls. No differences in
MRP-1 and MRP-4 expression were found in LNMC and
PBMC taken from the same patients on HAART.
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These advances should help us design new therapeutic
approaches for HIV, capable of overcoming the reservoir
problem.Page 2 of 2
(page number not for citation purposes)
